Chicago, IL (PRWEB) April 26, 2013
The birth control safety advocates at DrugRisks.com have added new information to the site for women using the contraceptives Yaz or Yasmin. A court recently ordered that Bayer no longer holds a patent on the drugs as the company continues to settle claims from patients alleging blood clot injuries**.
DrugRisks was created to give patients taking popular prescription drugs like Yaz and Yasmin the latest warnings, recalls, studies and legal news. With access to clear information, patients can discuss side effect concerns with their doctor and decide if they need legal advice.
The British Medical Journal and FDA have cautioned that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%*.
With a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
Now, DrugRisks has added information showing the U.S. Circuit Court of Appeals for Washington last week ruled Bayer’s patent on Yaz, which was set to expire in 2014, is no longer valid**. This will allows competitors Actavis, Sandoz and Lupin to continue selling their generic versions of the drug**.
Bayer’s latest financial reports show the company has spent nearly $1 billion to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis***.
Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is
Copyright©2012 Vocus, Inc.
All rights reserved